VINCENT
Venetoclax plus azacitidine versus standard intensive chemotherapy for patients with newly diagnosed acute myeloid leukemia (AML) and NPM1 mutations eligible for intensive treatment.
| Studienleiter | Prof. Dr. Christoph Röllig |
| EU CT-Nr. | 2024-515267-59-00 |
| Studientyp | Phase II |
| Indikation | AML |
| ClinicalTrial | NCT05904106 |